On April 15, 2020 Nanjing Kati Medical Technology Co., Ltd. (hereinafter referred to as Kati Medical) and Nanjing Shenghe Pharmaceutical Co., Ltd. (hereinafter referred to as Shenghe Pharmaceutical) signed a strategic cooperation agreement in the Medical Valley of Jiangbei New District, Nanjing. Wang Enxiu, chairman of Kati Medical, and Zhao Liwen, deputy general manager and director of the research institute of Shenghe Pharmaceutical, signed a strategic cooperation agreement on behalf of both companies. Luo Shuqin, deputy director of the Life and Health Office of Nanjing Jiangbei New District, witnessed the signing (Press release, CART Medical, APR 15, 2020, View Source [SID1234639851]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This signing is the beginning of cooperation between the two parties. In the future, the two parties will use this as a starting point to gradually upgrade the level of strategic cooperation and achieve win-win development.
Shenghe Pharmaceutical cherishes this opportunity to cooperate with Kati Medical and believes that through this cooperation, it will promote the rapid development of tumor immunotherapy technology.
Nanjing Biomedicine Valley relies on the national major new drug creation and major scientific and technological achievement transfer pilot demonstration bases to forge ahead and strive to be the source of innovation in the pharmaceutical field. It now includes Kati Medical, Simcere TECO, Luye Pharmaceutical, Nanwei Medical, Jianyou Biochemistry, etc.
There are more than 800 companies related to the comprehensive health industry chain. It is hoped that through the strategic cooperation between Kati Medical and Shenghe Pharmaceutical, the continuous innovation of CAR-T treatment technology will be promoted; with the smooth development of the strategic cooperation between the two parties, more people will enjoy the joy of health in the future.
Through this strategic cooperation, the two parties will achieve complementary advantages and strong alliances to jointly build a new chapter in the development of tumor immunotherapy technology!